【摘要】 目的 :探讨急性冠脉综合征(ACS)早期辅助应用中药麝香保心丸(SXBXW )治疗有效性、安全性和预防心脑血管事件的益处。方法 :将 15 3例ACS病人随机单盲分为两组 :SXBXW组 (治疗组 ) 77例 ,SXBXW每次 2丸 (每丸 2 2 .5mg) ,1日 3次 ;安慰剂组 (对照组 ) 76例 ,安慰剂每次 2粒 ,1日 3次。两组均按ACS常规治疗 ,且随访 1年 ,观察两组抗心绞痛疗效、心功能改变、心脑血管事件发生情况及不良反应发生情况。结果 :治疗组显著改善心绞痛 (AP)症状 (总有效率 88.3 % ) ;改善AP的缺血心电图(总有效率 5 7.4% ) ,二者均优于对照组 (P均 <0 .0 5 ) ;治疗组随访 1年中复发性AP、非致死性心肌梗死 (MI)、心力衰竭 (HF)、需做经皮腔内冠脉成形术 /冠脉旁路移植术 (PTCA/CABG)、需再住院治疗的病例均较对照组明显降低 (P <0 .0 5 ) ;SXBXW治疗 3个月明显改善左心室射血分数(LVEF)、左心室短轴缩短率 (FS)、二尖瓣快速充盈期和心房收缩期血流速度比 (E/A) ,且明显优于对照组 (P均<0 .0 5 )。治疗组降低C -反应蛋白(CRP)、纤维蛋白原 (FIB)和D -二聚体作用均明显优于对照组 (P均 <0 .0 5 ) ,且SXBXW辅助治疗ACS不良反应轻微。结论 :ACS早期辅助应用SXBXW有效安全 ,可预防心脑血管事件发生 ,作为辅助药物之一值得推广应用。更多还原

【Abstract】 Objective:To observe the clinical effect and safety of traditionary Chinese medicine Shexiang Baoxinwan (SXBXW) in acute coronary syndrome (ACS) as an ancillary treatment.Methods:153 cases of ACS were assigned two groups randomly and simple blindly. In addition to standard treatment of ACS, one group ( treatment group,n=77) was added SXBXW 2 pills three times per day; the other was given placebo as control. All cases were followed up 1 year, and the effect of treatment, the changing in cardiac function and the occurrence of cardiocerebral events were observed.Results:The severity and reoccurrence of angina pectoris were decreased significantly in treatment group (total effective rate 88.3%,P<0.05). In treatment group, the ischemic electrocardiograph also was significantly improved (total effective rate 57.4%, P<0.05). The events such as recured angina pectoris, nonfatal acute myocardial infarction, heart failure , the need for percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass grafty (CABG) and the rate of re-hospitalizing were significantly lower in treatment group (P<0.05). Left ventricular ejective fraction (LVEF), fractional shortening of minor-semi axis (FS), the ratio of peak flow velocity between early diastole and atrial contraction (E/A) were great significantly 3 months later in the treatment group than the control .(all P<0.05). CRP, FIB and D-dimer were significantly decreased in the treatment group too. And The adverse reactions were similar and mild in the two groups.Conclusion:SXBXW is safe and more effective assistant treatment in acute coronary syndrome.更多还原